CClinicalTrials.gg
WithdrawnNCT02103946SAMUpdated Apr 10, 2018

Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia

An interventional study of Serratus Anterior Muscle Plane block (SAM block) and Paravertebral Block in Breast Cancer and Acute Pain, sponsored by National Cancer Institute, Egypt. Withdrawn at 1 site in Egypt. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-04-10.

Sponsored by National Cancer Institute, Egypt · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Study summary

ًًًُُُُThe investigators are testing the efficacy of a new novel technique; serratus anterior plane block, for preventing postoperative pain after breast surgery for cancer. This block will be compared with the well-established paravertebral block.

Read the detailed description

Paravertebral block (PVB) can be considered as a well-established option to provide anesthesia and postoperative analgesia during breast surgery. For patients receiving a PVB alone or in combination with general anesthesia significant lower resting, evoked and worst pain scores compared with other analgesic treatment strategies indicating that a PVB provides improved postoperative pain control in patients undergoing breast surgery. Furthermore, there might be a reduced need for postoperative opioid requirements and consecutively a decrease in opioid-induced adverse effects in patients receiving a PVB. Anyways there are always fear of pleural injury and pneumothorax in addition to epidural and intrathecal spread of the block. A novel newly introduced field block has been described recently to block the hemithorax under ultrasound guidance that is the Serratus Anterior Muscle Plane SAM block. Still this technique to the investigators knowledge is not tried in randomized clinical studies. The aim of this study is to find out that this new technique is comparable to PVB in patients undergoing breast surgeries with or without axillary node dissection.

02

Conditions studied

  • Breast Cancer
  • Acute Pain

Keywords

  • serratus
  • paravertebral
  • breast
  • cancer
  • axilla
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

Browse Breast Neoplasms studies →

Lead sponsor

National Cancer Institute, Egypt is the lead sponsor of 133 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • unilateral mastectomy with or without axillary lymph node dissection.
  • American Society of Anesthesia (ASA) I\&II

Exclusion criteria

Exclusion Criteria:

  • morbid obesity (body mass index > 40 kg/m2);
  • renal insufficiency (creatinine > 1.5 mg/dL),
  • current chronic analgesic therapy (daily use > 4 weeks),
  • a history of opioid dependence, pregnancy,
  • inability to communicate with the investigators or hospital staff,
  • American Society of Anesthesia (ASA) III-IV
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Serratus anterior muscle plane block

    Serratus anterior muscle plane block with general anesthesia MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\\Kg Fentanyl, 1-2 mic\\Kg Paracetamol, 1000 mg\\6 hours Fam® (Ketorolac), 30 mg

    Procedure: Serratus Anterior Muscle Plane block (SAM block)

  • Active comparator
    Paravertebral block

    Paravertebral block with general anesthesia. MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\\Kg Fentanyl, 1-2 mic\\Kg Paracetamol, 1000 mg\\6 hours Fam® (Ketorolac), 30 mg

    Procedure: Paravertebral Block

Interventions

  • ProcedureSerratus Anterior Muscle Plane block (SAM block)

    The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.

    Also known as: Serratus anterior block, intercostal nerve block

  • ProcedureParavertebral Block

    After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.

    Also known as: Thoracic Paravertebral block

06

What researchers measure

Primary outcomes

  1. pain relief

    reduction of pain intensities in the first postoperative day after breast surgery for cancer.

    Time frame: first postoperative day

Secondary outcomes

  1. opioid consumption

    intraoperative and postoperative opioid consumption

    Time frame: intraoperative and first postoperative day

Other outcomes

  1. patient satisfaction

    measure patient satisfaction a week after surgery

    Time frame: first week after surgery

07

Study locations

1 site
  • National Cancer Institute
    Cairo, Kasr Alainy 11796, Egypt
08

References and documents

Publications

  • Schnabel A, Reichl SU, Kranke P, Pogatzki-Zahn EM, Zahn PK. Efficacy and safety of paravertebral blocks in breast surgery: a meta-analysis of randomized controlled trials. Br J Anaesth. 2010 Dec;105(6):842-52. doi: 10.1093/bja/aeq265. Epub 2010 Oct 14. Erratum In: Br J Anaesth. 2013 Sep;111(3):522. PubMed 20947592 ↗
  • Mendoza TR, Chen C, Brugger A, Hubbard R, Snabes M, Palmer SN, Zhang Q, Cleeland CS. The utility and validity of the modified brief pain inventory in a multiple-dose postoperative analgesic trial. Clin J Pain. 2004 Sep-Oct;20(5):357-62. doi: 10.1097/00002508-200409000-00011. PubMed 15322443 ↗
  • Blanco R, Parras T, McDonnell JG, Prats-Galino A. Serratus plane block: a novel ultrasound-guided thoracic wall nerve block. Anaesthesia. 2013 Nov;68(11):1107-13. doi: 10.1111/anae.12344. Epub 2013 Aug 7. PubMed 23923989 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02103946
Lead sponsor
National Cancer Institute, Egypt
Responsible party
Ghada M N Bashandy (Dr, National Cancer Institute, Egypt) — Principal investigator
First posted
Apr 4, 2014
Start date
Apr 2014
Primary completion
Jul 2014
Completion
Aug 2014
Last update
Apr 10, 2018

Study contacts

Ghada MN Bashandy, MD
principal investigator · Lecturer of anesthesia & pain relief

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion